Rectify Pharma bets on proteins that need a helping hand

A cystic-fibrosis lesson became a $100 million biotech bet: help faulty membrane proteins do their jobs. Rectify’s lead liver-disease candidate is now in Phase 1, with a kidney-disease partnership behind it.